Europe – October 27, 2026 -- Continuous glucose monitoring (CGM) was associated with a 45% lower risk of death at one year among adults with type 2 diabetes on basal insulin, according to a study presented at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting.
The analysis used Truveta Data to track nearly 28,000 adults with type 2 diabetes receiving basal insulin therapy. Researchers combined longitudinal electronic health record (EHR) and mortality data in a target trial emulation that compared CGM users with non-users.
CGM users show 36% lower two-year mortality risk
At one year, CGM users had a 45% lower risk of death from any cause than non-users. At two years, the reduction was 36%.
Heart failure hospitalizations roughly halve among CGM users
CGM users also had lower risks of heart attack, stroke, peripheral artery disease, and heart failure hospitalization. Heart failure hospitalizations were approximately half as common among CGM users at both one and two years.
The study was observational, so the findings show an association only. They cannot establish that CGM directly caused the lower rates of death or cardiovascular events.